An Open Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials - Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium

Author:

Koneswarakantha Björn1ORCID,Adyanthaya Ronojit2,Emerson Jennifer3,Collin Frederik3,Keller Annett3,Mattheus Michaela3,Spyroglou Ioannis2,Donevska Sandra2,Ménard Timothé1ORCID

Affiliation:

1. F. Hoffmann-La Roche AG

2. Merck & Co. Inc

3. Boehringer Ingelheim Pharma GmbH & Co KG

Abstract

Abstract

Accurate and timely reporting of adverse events (AE) in clinical trials is crucial to ensuring data integrity and patient safety. However, AE under-reporting remains a challenge, often highlighted in Good Clinical Practice (GCP) audits and inspections. Traditional detection methods, such as on-site investigator audits via manual source data verification (SDV), have limitations. Addressing this, the open-source R package {simaerep} was developed to facilitate rapid, comprehensive, and near-real-time detection of AE under-reporting at each clinical trial site. This package leverages patient-level AE and visit data for its analyses. To validate its efficacy, three member companies from the Inter-coMPany quALity Analytics (IMPALA) consortium independently assessed the package. Results showed that {simaerep} consistently and effectively identified AE under-reporting across all three companies, particularly when there were significant differences in AE rates between compliant and non-compliant sites. Furthermore, {simaerep}'s detection rates surpassed heuristic methods, and it identified 50% of all detectable sites as early as 25% into the designated study duration. The open-source package can be embedded into audits to enable fast, holistic and repeatable quality oversight of clinical trials.

Publisher

Research Square Platform LLC

Reference22 articles.

1. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6(R2).GuidelineforGoodClinicalPractices.2016https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.Accessedon12-DEC-2023.

2. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E8(R1).GuidelineonGeneralConsiderationsforClinicalStudies.2021.https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf.Accessedon12-DEC-2023.

3. Food and Drug Administration.GuidanceforIndustry:InvestigatorResponsibilities—ProtectingtheRights,Safety,andWelfareofStudySubjects.2009.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM187772.pdf.Accessedon12-DEC-2023.

4. Medicine and Healthcare products Regulatory Agency.GCPinspectionmetricsreport.https://assets.publishing.service.gov.uk/media/64357bfe89f19f00133cfb40/GCP_inspection_metrics_2019-2020.pdf.2023.Accessedon12-DEC-2023.

5. Food and Drug Administration.Clinical Investigator Inspection List (CLIIL).https://www.fda.gov/drugs/drug-approvals-and-databases/clinical-investigator-inspection-list-cliil.Accessed on 12-DEC-2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3